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Abstract: The theranostic approach to local tuberculosis treatment allows drug delivery and imaging
of the lungs for a better control and personalization of antibiotic therapy. Metal-organic framework
(MOF) Fe-MIL-101-NH2 nanoparticles were loaded with isoniazid. To optimize their functionality a
23 factorial design of spray-drying with poly(lactide-co-glycolide) and leucine was employed. Powder
aerodynamic properties were assessed using a twin stage impinger based on the dose emitted and the
fine particle fraction. Magnetic resonance imaging (MRI) contrast capabilities were tested on porous
lung tissue phantom and ex vivo rat lungs. Cell viability and uptake studies were conducted on
murine macrophages RAW 246.9. The final product showed good aerodynamic properties, modified
drug release, easier uptake by macrophages in relation to raw isoniazid-MOF, and MRI contrast
capabilities. Starting from raw MOF, a fully functional inhalable theranostic system with a potential
application in personalized tuberculosis pulmonary therapy was developed.
Keywords: theranostic agent; tuberculosis (TB); local pulmonary delivery; isoniazid (INH);
metal-organic frameworks (MOF); personalized inhaled therapy; inhaled microparticles; inhalable
spray-dried powder blends; ultrashort echo time magnetic resonance imaging (UTE MRI); porous
lung tissue phantom
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1. Introduction
The deceptive nature of tuberculosis (TB) contributed to its long-time reputation of curable and
defeated disease. Alongside poor health care settings and treatment control, limited understanding of
TB infection peculiarities and the complex host-pathogen crosstalk have crippled progresses in the field.
Current therapies rely on cumbersome, lengthy multidrug treatments that, albeit still effective at early
infection stages, lose efficacy rapidly at later disease phases and on latent infections. A dramatic but
inevitable consequence is the alarming worldwide growth of drug resistance that has undermined the
sustainability and efficacy of current TB treatments. This scenario also partially explains the general
crisis of the antibiotic drug market. On the other hand, a renewed awareness and increased knowledge
of TB infection features have encouraged recent efforts towards the development of host-directed
approaches and inhaled TB therapies. Undoubtedly, pulmonary anti-TB drug delivery is the logical
strategy for maintaining local therapeutically effective concentrations while avoiding massive systemic
exposure and consequently reducing side effects [1,2].
However, the efficacy of inhaled antibiotic treatments is strictly dependent on drug deposition
patterns within the lungs, which in turn are determined by the formulation performances and
pathophysiological factors [3,4]. Even when proper susceptibility screening and optimal formulations
are being adopted, disease-related impairment of conductive airways can cause insufficient delivery
to the infected sites, resulting in sub-effective local antibiotic levels. Such an issue is detrimental to
treatment efficacy, raising serious resistance development concerns. Moreover, the often neglected
large individual variability in lung capacity and physiology reduces further the chances of success of
inhaled antibiotic therapies [5]. The disease-induced lack of access to poorly-aerated lung regions is
hard to detect clinically. In fact, healthy conductive airways may compensate such an impairment,
masking the partial improper ventilation to standard functional lung tests, such as spirometry [6].
Therefore, the assessment of infection-related lung function alterations is a priority in order
to establish proper countermeasures enabling effective drug deposition within the lungs [5].
To discriminate between the effect of the delivery mechanism and the pharmacological action, it is
crucial to (i) properly assess the effectiveness of the treatment, (ii) adjust the appropriate dose, and (iii)
prevent false negative treatment results. In this regard, the development of functional lung imaging
methods, such as magnetic resonance imaging (MRI), may help to discriminate between drug and
pathophysiological effects [7,8].
When diagnosing pulmonary diseases, the MRI can be used to detect disease-induced changes in
the lungs [9–11]. MRI is especially attractive when dealing with pediatric patients [12] and pregnant
women [13]. MRI methods designed for signal acquisition from environments exhibiting very short
T2/T2* relaxation times (property of lung tissue/environment), like ultra short echo time (UTE) and
zero echo time (ZTE) [14], have demonstrated their correlations with X-ray computed tomography
(CT) [12]. Moreover, UTE has been applied to study aerosol deposition using iron oxide particles ex
vivo [15,16] and gadolinium (Gd)-DOTA particles in vivo [17,18].
These techniques may enable treatment personalization, and thus, maximizing therapeutic
outcomes by granting control over lung deposition and local drug levels [5,19]. Although theoretically
feasible, inhalation treatment personalization through imaging techniques is not an easy task and
requires the development of proper tools to record a patient’s conditions and inhalation behavior.
In this regard, the concept of theranostic is in the spotlight in personalized medicine [20–22].
The term “theranostic” was coined by merging the words therapy and diagnostics. A classical
theranostic agent is defined as a system enabling simultaneous monitoring of drug delivery and
treatment outcomes so as to allow a proper therapy–patient match [23,24]. Nowadays, nanotechnology
has allowed the combination of such features even into a single particle, coupling an effective delivery
approach with imaging capabilities [25]. In this regard, functional imaging has the potential to provide
new insights into the behavior of inhaled particles by allowing monitoring of deposition patterns
upon administration. The possibility of tracking particles after inhalation may allow one to assess
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the actual drug targeting to the infected sites and personalized dose adjustments. This may grant
patient-centered therapeutic regimens and administration strategies.
Metal-organic frameworks (MOFs) are porous materials whose structures are built by inorganic
single ion or ion cluster nodes joined together by organic linkers [26,27]. Their characteristic feature
is the presence of a metal center, which may be a paramagnetic cation (e.g., iron), responsible for
the MRI contrast property [28,29]. In our previous study, we presented the possibility of application
of Fe-MIL-101-NH2 MOF, consisting of Fe (III) and 2-aminoterephthalic acid, as a controlled release
carrier for isoniazid (INH) and an MRI contrast agent [29]. The results suggest that Fe-MIL-101-NH2
loaded with the drug can serve as an effective MRI contrast agent and can be used as a foundation
for constructing actual drug delivery systems. The in vitro cytotoxicity studies of Fe-MIL-101-NH2
confirmed its safety and the accumulation observed in the cell cytoplasm supports a potential
application in pulmonary tuberculosis therapy [29].
Despite extensive studies concerning potential pharmaceutical MOF applications [28–32], there is
still an unmet need for effective MOF-based drug delivery systems.
Particularly for inhaled TB therapy, MOFs show a number of limitations that require tailoring
of their physico-chemical and solid-state properties. In this regard, our preliminary studies have
shown that INH-loaded MOF (INH-MOF) display insufficient aerodynamic performances to stand
alone as an inhaled dosage form. Moreover, proper formulation approaches are needed to ensure
INH-MOF macrophage uptake, which is a recognized strategy to enable successful targeting of primary
TB infection sites and prevention of further infection spreading [33,34].
Therefore, the main goal of this study was to formulate an INH-MOF based theranostic system
showing optimal aerodynamic properties using the spray drying technology. For this purpose,
hydrophobic and hydrophilic microparticles (MPs) loaded with INH-MOF were prepared to provide
appropriate formulation flowability and prolonged drug release. Particles were blended and
characterized for their aerodynamic behavior, morphology, in vitro drug release, biocompatibility and
MRI contrast capabilities.
2. Experimental Section
2.1. Materials
Isoniazid, D-Leucine (LC), poly(lactide-co-glycolide) (PLGA, Resomer® RG504H), tetrabutylammonium
hydroxide solution (tBAH), HPLC-grade acetonitrile (ACN), and trifluoroacetic acid (TFA) were from
Sigma-Aldrich (Taufkirchen, Germany). PrestoBlueTM test, a dichloro-dihydro-fluorescein diacetate
(H2DCFDA) assay kit were purchased from ThermoFisher and ToxiLight from Lonza. Murine
macrophages—RAW 246.9 cell line—Were obtained from ATTC. Macrophage Detachment Solution
was from Promocell.
2.2. MOF Synthesis and Drug Incorporation
Fe-MIL-101-NH2 was synthesized according to the procedure reported by Bauer et al. [35]. After
drying, MOF was activated under vacuum at 100 ◦C to remove residual solvent molecules. INH was
incorporated into the activated MOF by mixing 5 mL of saturated INH solution in DMF with 1000 mg
of Fe-MIL-101-NH2 for 12 h. The product was separated by centrifugation.
2.3. Preparation of Spray-Dried Particles
LC and PLGA MPs were prepared by spray-drying using the B290 Mini spray-dryer (Buchi, Flawil,
Switzerland). For PLGA MPs, MOF (with and without drug) was suspended in a 12 mL of ACN PLGA
solution. The total amount of solids was 400 mg and the process parameters were as follows: air
flow rate 357 L/h, inlet temperature 75 ◦C, aspirator rate 20 m3/h, feed rate 2.4 mL/min. For LC MPs,
LC and MOF were solubilized in 15 mL of water (total amount of solids 300 mg), and spray-drying
was performed at the following conditions: air flow rate 473 L/h, inlet temperature 140 ◦C, aspirator
rate 20 m3/h, feed rate 2.4 mL/min.
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2.4. Design of Experiment (DOE)
Blends were prepared by placing appropriate amounts of each powder in a tube (total amount
200 mg) and mixing them for a specified time at a speed of 60 rpm in a coclea mixer kept at an angle of
45◦. The effects of MOF loading (factor A), PLGA/LC blend ratio (factor B), and blending time (factor C)
were investigated on emitted dose (%ED) and fine particle fraction (%FPF) employing a 23 factorial
design (Table 1).
Table 1. 23 factorial design for the development of spray-dried INH-metal-organic framework
(MOF)-loaded microparticle (MP) blend and the respective response parameters. For the preparation a
hydrophobic and hydrophilic excipient were used: PLGA and LC. The blends were obtained changing
MOF amount, the PLGA/LC ratio, and blending time. The aerodynamic behavior of the blends was
assessed through the TSI test by measuring fine particle fraction (%FPF) and emitted dose (%ED).
The content homogeneity of the blends corresponding to each run is also reported.
Run
Factors
Responses Content
Homogeneity
p-Value (n = 9)
A B C
INH-MOF
Content [% w/w]
Blending Ratio [% w/w] Blending Time
[min] %FPF %EDPLGA LC
1 20 20 80 5 48.06 91.29 0.078
2 20 80 20 5 25.99 90.91 0.840
3 20 20 80 15 46.50 91.90 0.711
4 20 80 20 15 26.86 91.85 0.368
5 40 20 80 5 47.17 93.19 0.103
6 40 80 20 5 28.18 92.00 0.483
7 40 20 80 15 54.78 93.30 0.069
8 40 80 20 15 28.06 92.97 0.380
9 30 50 50 10 52.29 94.01 0.740
10 30 50 50 10 45.75 93.35 0.192
11 30 50 50 10 49.43 93.50 0.128
Design Expert version 8.0.1 software (Stat-Ease, Minneapolis, MN, USA) was used to evaluate the
effect of the selected factors on the properties of the blend. The selected variables were interpolated
with a quadratic polynomial equation (Equation (1)).
y = b0 +
k∑
i=1
bixi +
k∑
i=1
k∑
j=1
bi jxix j +
k∑
i=1
biix2i + e, (1)
where y is the response; b0, bi, bii, and bij are the regression coefficients; xi and xj are the level of the i-th
and j-th factors; and e is the residual random error of the model.
The models were statistically evaluated by ANOVA and response surfaces were built to evaluate
the effects of the three select factors on the aerodynamic behavior of the blend.
To define the conditions granting the desired characteristics, the obtained response surfaces were
combined by applying the total desirability approach [36], which is represented by Equation (2):
f (d(g)) =
∑M
i=1 widi∑M
i=1 wi
, (2)
where f (d(g)) is the total desirability, of the i-th response, M is the number of responses and w is the
weight of each response specified by the user. Desirability assumes values between 0 and 1 and the
maximum desirability corresponds to the conditions that provide compliance with the established
quality criteria.
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2.5. Particle Characterization
2.5.1. In Vitro Aerodynamic Characterization
Aerodynamic properties were assessed according to the European Pharmacopeia Ed. IX, using a
twin-stage impinger (TSI). The two stages of the TSI were filled with 7 mL (stage 1) and 30 mL (stage 2)
of 50:50 ACN: 0.1 M NaOH solution (extraction medium for placebo MPs) and 50:50 ACN: 0.01 M
phosphate buffer, pH 7.4 (for MPs containing INH). In total, 20 mg of powder was loaded into an
HPMC capsule (Type 3, Quali-V, Qualicaps® S.A.U, Romania, Spain). The air flow rate was set at 60 ±
5 L/min and emission was performed for 5 s through an RS01 model dry powder inhaler. The %ED
and %FPF were calculated using Equations (3) and (4):
%ED = emitted dose 100/Nominal dose (3)
% FPF = dose (stage 2) 100/Emitted dose (4)
2.5.2. MOF and Drug Quantification
MOF was analyzed by UV–vis spectrometry using an Agilent 8453 spectrophotometer. Samples
were sonicated during 20 s and analyzed (λmax = 325 nm). Calibration was performed in the
25–200 µg/mL concentration range in a 0.1 M NaOH solution (R2 = 0.9987).
INH was assayed by HPLC using a HP1050 chromatograph equipped with UV–Vis detector
set at 254 nm and a GROM-SIL 120 Diol 250 × 4.6 mm (Grace Davison Discovery Sciences) column.
Operating conditions were: column temperature 25 ◦C; flow rate 1 mL/min; the mobile phase was
70:30 ACN: 0.4 mM tBAH, pH 6. Calibration was performed in the 0.5–16 µg/mL concentration range
in water (R2 = 0.9997).
2.5.3. Sampling for Content Uniformity and Content Average
In total, 200 mg of formulation powder was spread over the surface of a circle with a 5.5 cm
diameter. The circle was divided into three slices and three samples (about 3 mg) were gently taken
from each slice and assayed as reported above. The average MOF/INH content was calculated on 9
replicates. Acceptance criteria were percent relative standard deviation (%RSD) ≤5%, and mean ± 10%
from target value according to USP 34.
2.5.4. Particle Size and Morphology
Particle size analysis of PLGA MPs was carried out by an Accusizer C770 particle counter (PSS,
Santa Barbara, CA, USA) equipped with an autodilution system. Due to LC solubility in water and
even partial solubility in organic solvents, the particle size of LC MPs was determined by scanning
electron microscopic (SEM) images, using Image J software. An average of 200 particles from at least
six different SEM images were counted and size distributions and mean diameters were calculated.
SEM analyses were performed by using a FEG LEO 1525 microscope (LEO Electron Microscopy
Inc., Thornwood, NY, USA). The acceleration potential voltage was 1 keV. Samples were placed onto
carbon tape coated aluminum stubs and sputter coated with chromium for 20 s at 20 mA (Quorum
Technologies, East Essex, UK). Additional observations were conducted on dispersed particles collected
from the impinger immediately after actuation. Energy dispersive X-rays spectroscopy (EDX) was
performed by detecting Fe and N signals at 10 kV with acquisition times of 20 min. The coating was
performed with graphite at 20 mA for 22 s.
2.6. In Vitro Drug Release Study
In vitro drug release experiments were performed by the dialysis bag method (12–14 kDa MWCO).
A 0.1 M phosphate buffer (pH 7.4) solution was employed as a release medium, using a 50 mL conical
Falcon tube incubated at 37 ◦C. An experiment was conducted for the optimized INH-MOF-loaded
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PLGA/LC MP blend, PLGA MPs, and LC MPs. Drug release quantification was performed in triplicate
by HPLC using the method described above.
2.7. Statistical Analysis
The results for statistical analysis are presented as the mean ± %RSD. One-way ANOVA and
descriptive statistics (software SigmaPlot, version: 14.0, San Jose, CA, USA) were employed to analyze
content uniformity in PLGA/LC MP blends. Dunnet’s and Tukey’s post-hoc methods were employed for
the evaluation of differences within and between groups. p values of < 0.05 were considered significant.
For the in vitro tests on cells, the bar-graph data show the means and standard deviations of one
representative of 6 independent measurements. Significant effects (p < 0.05) were determined using
the independent t-test, also called the two sample t-test, an inferential statistical test that determines
whether there is a statistically significant difference between the means in two unrelated groups.
The t-test was used to check differences between the samples cultured in the presence of MOF at
different concentrations and control but not to compare different MOF concentrations with each other.
2.8. Magnetic Resonance Imaging (MRI)
2.8.1. Preparation of Sponge Phantoms of Lung Tissue
A sponge phantom was prepared to reflect the structure of lung tissue. It consisted of three 2 × 2 ×
1 cm3 cellulose sponge bricks. Each sponge brick was wet with 1.5 mL of raw MOF water suspension,
hermitized, and retained for equilibration. The amount of MOF suspension was chosen to hydrate the
sample and left the largest pores liquid free. Sponges containing pure water and the highest MOF
concentration were fixed and between them the central one was replaceable. The concentrations of
MOF suspensions were 0 (pure water), 0.03, 0.0625, 0.125, 0.25, 0.5, and 0.75 mg/mL. Concentrations of
MOF in suspension corresponded to the mass of MOF per sponge volume of 0, 11.25, 23.25, 46.875,
93.75, 187.5, 281.25, and 375 µg/cm3. Fixed sponges were used for reproducibility testing, as they
allowed us to calculate mean values for six independent measurements (n = 6).
2.8.2. Preparation of Lung Ex Vivo Samples
The experiment was performed on excised Wistar rat lungs obtained from animal facility of
Faculty of Pharmacy Jagiellonian University Medical College. Appropriate amounts of the optimized
INH-MOF-loaded PLGA/LC MP blends, 3.75 and 18.77 mg (equivalent to 10% and 50% of the INH oral
dose) were administered into the lung via trachea. The lungs were stored in 0.9% NaCl solution and
transferred to 20 mm ID tubes. MOF concentration in the lung was calculated assuming the rat lung
volume of 3 mL [37].
2.8.3. MR Imaging and Image Analysis
Magnetic resonance imaging was performed using 9.4 T MRI research system (Bruker Biospin,
Rheinstetten, Germany). A 3D ultra short echo time (UTE3D) imaging sequence was used with
following parameters: echo time (TE) = 110 µs, repetition time (TR) = 2.345 ms, flip angle = 5◦, number
of accumulations (NA) = 1, number of radial projections = 52,402, and reconstructed 3D volume image
of 160 × 160 × 160 voxels. For sponge phantom imaging, field of view (FOV) was 45 × 45 × 45 mm3,
and for lung imaging it was 35 × 35 × 35 mm3.
3D volume images were imported to Fiji distribution of ImageJ version 1.44 (National Institutes of
Health, http://rsb.info.nih.gov/ij/) [38].
Concerning sponge phantoms, each sponge volume was extracted by 3D cropping, and for
the cropped volume images the histograms were calculated. The histograms were normalized to
the number of voxels in the image volume. The maximum value of each histogram was assessed.
The maximum histogram values obtained for MOF wetted samples were expressed as relative to the
maximum histogram value obtained for water wetted volume. The results for all measured MOF
concentrations were fitted (linear fit) using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA).
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3D binary mask of the lung volume was obtained as a result of image segmentation of the original
3D image volume. The supervised image segmentation was performed using a Trainable Weka
Segmentation 3D (TWS 3D) plug-in module (https://imagej.net/Trainable_Weka_Segmentation), part of
the public domain software, Fiji distribution (https://fiji.sc/) of ImageJ—built on Waikato Environment
for Knowledge Analysis (WEKA) data mining and machine learning toolkit [39]. The binary mask and
the original image were multiplied (voxel by voxel multiplication). For the segmented volume images,
the histograms were calculated and normalized to the total number of counts. Finally, rendered fine
structure of the lungs was visualized using 3D Viewer plugin.
2.9. In Vitro Study—Cell Viability, Cytoxicity, and Cellular Uptake
RAW 246.9 was grown in Dulbecco’s modified Eagle’s medium, DMEM, with the addition of
10% (v/v) fetal bovine serum. Cells were cultured in a humidified atmosphere at 37 ◦C with 5% CO2,
incubated until an 80% confluent cell monolayer was developed, and detached from the culture flasks
using Macrophage Detachment Solution. The experiment wasdivided into two stages. First, cells
were plated at the density of 5 × 103 cells/well in a 96-well plate, and after 24 h were incubated with
various MOF concentrations (500, 100, 50, 25, and 10 µg/mL). Based on results obtained for pure
MOF, 100 µg/mL was chosen as the optimal MOF concentration for further study. In the next step,
cells were plated at the density of 200 × 103 cells/well in a 24-well plate. After 24 h of incubation,
cells were exposed to blend and a corresponding quantity of INH-MOF at concentrations 500 and
150 µg/mL, respectively.
Cells were incubated for 24 h in standard conditions, and after that, the viability, cytotoxicity, and
level of ROS were determined.
Cell viability was examined by resazurin-based reagent PrestoBlueTM. Material cytotoxicity was
determined by ToxiLightTM BioAssay Kit and ToxiLightTM 100% Lysis Reagent Set.
The effect of materials on the level of reactive oxygen species (ROS) was investigated using
dichloro-dihydro-fluorescein diacetate (H2DCFDA) assay. As a positive control, 100 µM H2O2 was used.
The cell viability, toxicity, and ROS generation level were evaluated following the manufacturer’s
protocols for fluorescence or luminescence measurement using a microplate reader POLARstar Omega
(BMG Labtech, Ortenberg, Germany). Cell morphology was observed under contrast phase inverted
microscope CKX53 (Olympus, Tokyo, Japan).
The amount of phagocytosed INH by macrophages after treatment with INH-MOF and the
optimized INH-MOF-loaded PLGA/LC MP blend was examined after 0.5, 3, 6, and 24 h. Supernatants
were collected, and cells were washed by PBS and lysed by a 5% solution of Triton X-100 for 30 min.
To analyze lysates, the gradient reverse-phase high-performance liquid chromatography (RP-HPLC)
method was developed. The chromatographic separation of INH from formulation ingredients was
carried out on a Kinetex XB C18, 2.6 µm (150 × 4.6 mm) column with a mobile phase composed of
A: 0.1% TFA in water and a mobile phase B: 0.1% TFA in ACN. The flow rate was 0.4 mL/min and
detection was monitored at 254 nm.
3. Results
3.1. Experimental Design
The INH content in the INH-MOF used to prepare the formulation was about 12% [29]. The
development and optimization of an INH-MOF inhaled theranostic formulation was carried out
by applying a 23 factorial design. In order to meet the fundamental requirements of proper
nebulization, deposition, and pulmonary retention, INH-MOF was encapsulated in hydrophobic
poly(lactide-co-glycolide) (PLGA) MPs by spray-drying and blended with spray-dried INH-MOF-
loaded D-leucine (LC) MPs.
The aerodynamic properties of the blends were investigated in terms of emitted dose (%ED;
the amount of powder released from the device) and fine particle fraction (%FPF; the amount of powder
deposited in the 2nd stage of the TSI that corresponds to the lower lung airways). The design space
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for formulation optimization is presented in Table 1. The independent variables consistED of MOF
content, blending ratio, and blending time. The responses were %ED and %FPF, which describe the
aerodynamic behavior of the PLGA/LC MP blends.
As pointed out by the coefficient estimates calculated for the two quadratic models (Table S1 in
Supplementary), the percentage of LC MPs in the blend had a dominant effect on %FPF. In fact, %FPF
reached values >50% when the PLGA/LC ratio was <30% (Figure 1). Blending PLGA MPs with LC
MPs improved, considerably, the respirability of the powders compared with the poor behavior of
MOF and the PLGA MPs alone (%FPF < 30%), confirming the fundamental glidant role of LC, as also
observed by others [40].Pharmaceutics 2020, 12, x FOR PEER REVIEW 9 of 25 
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Figure 1. Surface plots depicting the effect of MOF content and the PLGA/LC ratio in %FPF and %ED.
The desirability surface plot is also reported, indicating the conditions simultaneously satisfying the
requirements of high %FPF and %ED, which grant the desired aerodynamic behavior. Color map:
red = high values, blue = low values.
Pharmaceutics 2019, 11, 687 9 of 25
The concomitant loading of INH-MOF in both the hydrophobic and hydrophilic MPs was thought
to limit the drug dilution effect resulting from the use of multiple excipients.
An important and non-linear effect of MOF loading on %FPF was observed. In contrast, %ED was
not much influenced by MOF loading with values always higher than 91%, regardless of the amount of
MOF encapsulated. The best aerodynamic performances were achieved at the MOF content value of
about 30% w/w. Blending time was generally uninfluential, on both %FPF and %ED (Table S1). Overall,
the models obtained indicated that target conditions could be fulfilled at about 30% MOF content and a
PLGA/LC ratio between 30% and 40%. These working coordinates provided blends with a theoretical
%FPF close to 60% and an %ED >93%.
Therefore, the final blending conditions were established at 30% MOF-INH loaded MP blended,
at 30% PLGA/LC ratio for 15 min. The measured values of %FPF = 56.7 (%RSD = 2.30) and %ED = 90.9
(%RSD = 1.18) indicated good aerodynamic powder properties and confirmed model predictivity.
3.2. Powder Characterization
3.2.1. Morphology and Size
MOF loading in LC and PLGA MPs produced rather irregular particles due to the presence of
bipyramidal MOF crystals (Figure 2).
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The encapsulation of MOF crystals produced fragile MPs, particularly LC MPs, that were partially
fragmented during blending (Figure 3a). This resulted in broad particle size distributions with average
volume-weighted diameters around 11 µm for MOF and 20 µm for PLGA MPs, while number-weighed
diameters were from 0.9 µm for MOF to 4.2 µm for PLGA MPs and 6.7 µm for LC MPs (Figure 3b).
Such size features suggest a compliance with pulmonary delivery requirements. In fact, it is suggested
that the small particle size below 5 µm may grant better inhalation efficacy than larger particle size
aerosols, owing to an enhanced penetration and retention in the lungs even in the presence of airway
narrowing [41,42]. In particle size distribution of INH-MOF PLGA MPs (Figure 3b) two populations
were observed: one corresponding to the particles and another to the free INH-MOF, which indicates
the presence of MOF also on the surface of the INH-MOF PLGA MPs.
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3.2.2. In Vitro Aerodynamic Characterization and Content Uniformity
The TSI study showed that the MPs blend aerodynamic behavior was a measure of the presence
of large clusters in the pow er. In fact, particle clusters >10 µ were deposited in the stag 1 of the
TSI, while the sma ler aggregat s (below 10 µm) we e a l fo nd in the stage 2 (Figure 4). Therefore, this
size cutoff was considered discriminativ in determining respirability of the obtained blends.
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Figure 4. SEM images of the dispersed optimized INH-MOF-loaded optimized PLGA/LC MP
blend—Powders deposited in the stage 1 and stage 2 of a twin stage impinger (TSI). The 2nd stage of
TSI corresponds to the lower lung part in which the drug is intended to act.
As reported in Table 1, a good content uniformity was measured either in the blends or the PLGA
and LC MPs (Table S2 in Supplementary), with only the samples from runs 3, 5, and 6 showing %RSDs
>5. However, only the blends from runs 9–11 had the target value within ± 10% of the calculated mean
(Table S3 in Supplementary). In all the other cases, the actual content was significantly higher than the
nominal one, especially at 40% theoretical loading. The measured homogeneity was consistent with
the homogeneous distribution recorded by EDX mapping (Figure 5). In fact, INH-MOF was partially
evenly distributed on the surface of particles (Figure 5), which confirms observation in the particle size
distribution of INH-MOF PLGA MPs (Figure 3b). High MOF content and an even distribution are
important to ensure tracking capacity of the inhaled blend. The average content of INH in the final
blend was 3.7% w/w (%RSD = 3.7).
3.3. In Vitro Drug Release Study
The drug was released faster during the initial 10 h than in the subsequent time period (Figure 6).
As a result of the excipient properties, a higher INH release was observed for LC MPs compared to
PLGA MPs (80% versus 59%, after 24 h). Since LC is water-soluble, a relatively fast LC MP dissolution
was expected with simultaneous drug release. Therefore, the release from LC MPs depended on the
intrinsic affinity of INH to MOF and MOF matrix degradation [28]. In fact, although LC MPs dissolve
immediately, INH dissolution was controlled by MOF, especially at neutral pH, which determined
the slow INH release. On the other hand, the hydrophobic nature of PLGA moderately reduced the
initial phase of drug dissolution. Drug release from PLGA MPs was assumed to be the result of more
complex hydration and diffusion processes. The hydrophobic properties of PLGA may explain the
incomplete release of INH from PLGA MPs [43].
Pharmaceutics 2019, 11, 687 12 of 25
Pharmaceutics 2020, 12, x FOR PEER REVIEW 13 of 25 
 
 
Figure 5. (a) EDX analysis of INH-MOF; (b) optimized INH-MOF-loaded PLGA/LC MP blend. 
Mapping shows nitrogen (purple) and iron (yellow) distributions. 
3.3. In Vitro Drug Release Study 
The drug was released faster during the initial 10 h than in the subsequent time period (Figure 
6). As a result of the excipient properties, a higher INH release was observed for LC MPs compared 
to PLGA MPs (80% versus 59%, after 24 h). Since LC is water-soluble, a relatively fast LC MP 
dissolution was expected with simultaneous drug release. Therefore, the release from LC MPs 
depended on the intrinsic affinity of INH to MOF and MOF matrix degradation [28]. In fact, 
although LC MPs dissolve immediately, INH dissolution was controlled by MOF, especially at 
neutral pH, which determined the slow INH release. On the other hand, the hydrophobic nature of 
PLGA moderately reduced the initial phase of drug dissolution. Drug release from PLGA MPs was 
assumed to be the result of more complex hydration and diffusion processes. The hydrophobic 
properties of PLGA may explain the incomplete release of INH from PLGA MPs [43]. 
Figure 5. (a) EDX analysis of INH-MOF; (b) optimized INH-MOF-loaded PLGA/LC MP blend. Mapping
shows nitrogen (purple) and iron (yellow) distributions.
Blending of hydrophilic and hydrophobic particles is to provide dual release of a drug. LC is very
soluble in contact with fluids and provides quicker release of INH-MOF compared to PLGA MPs. The
expected influence of both PLGA and LC MP properties on the INH release profile from the blend
produced a biphasic behavior with about 34% and 67% of drug release after 1 and 24 h, respectively.
The release was complete after about 4 days either for LC MP or the optimized blend.
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the optimized, INH-MOF-loaded PLGA/LC MP blend (0.1 M phosphate buffer, pH 7.4, 37 ◦C; n = 3).
Inclusion: magnification of the initial part of the dissolution profile.
3.4. MRI Contrast Capabilities
For all samples, the max mum histogram value obtained for an exchangeable sponge was between
the maximum of the histogram obtained for the water wetted sponge and the maximum obtained for
the sponge containing 375 µg of MOF per cm3. An example of the resultant histograms obtained using
exchangeable sponge phantom containing 11.25 µg of MOF per cm3 is presented in the left panel of
Figure 7d.
In the right panel of Figure 7d final results are presented; i.e., the dependence of relative maximum
histogram value on MOF concentration in the sponge, as expressed in dry MOF mass per volume of
the sponge brick (where the value 1 corresponds to the maximum histogram value for water wetted
sponge brick). At the lowest MOF concentrations, i.e., between 11.25 and 93.75 µg/cm3, the difference
between the maximum histogram values for pure water and the MOF wetted sponges was about
10–30% of the water histogram’s maximum. For the highest measured MOF concentration (375 µg/cm3)
the maximum of the histogram was as low as 0.6 of water maximum histogram value.
Concerning reproducibility, for water wetted sponge brick the mean maximum histogram value
was 17.026 × 10−3 ± 0.937 × 10−3. For the 375 µg/cm3 bricks the average histogram maximum
value was 10.254 × 10−3 ± 0.824 × 10−3 in absolute values and 0.575 ± 0.046 relatively to the water
histogram maximum.
Figure 8 shows the MRI results obtained for extracted rat lungs treated with optimized
INH-MOF-loaded PLGA/LC MP’s blend. An example of one slice of the 3D image volume for
untreated rat tissue is presented in the left panel of Figure 8a. A rendered 3D lung image based on
segmented volume is presented in the right panel of Figure 8a. Histograms of the three image volumes,
i.e., untreated lungs, treated with formulation dose fixed at 10% of an oral dose (MOF concentration in
the lung of 375 µg/cm3) and treated with dose fixed at 50% of oral dose (MOF concentration in the
lung of 1875 µg/cm3), are presented in Figure 8b. Histograms of the MR images of rat lungs followed
the same pattern as obtained on sponge fantom; i.e., decrease in max histogram value and overall
expansion towards higher image intensities with an increase in MOF concentration per volume of the
Pharmaceutics 2019, 11, 687 14 of 25
sample. Moreover, rendered fine details of lung structure are shown in Figure 8c. Upper left panel
of Figure 8c presents structural details for untreated lungs and upper right panel of Figure 8c for the
rat treated with dose containing MOF at a concentration of 375 µg/cm3. The lower panel of Figure 8c
presents fine lung structural details for rat treated with dose containing MOF at a concentration of
1875 µg/cm3. The comparison of the untreated lungs and the lungs treated with final formulation at
various MOF concentrations showed enhancement of the bronchi structure as a result of the MOF
presence in the formulation powder at the surface of various parts of the tract (e.g., at bronchi walls).
Not only primary and secondary, but also tertiary bronchi were able to visualize (inside the yellow
ring in Figure 8c).Pharmaceutics 2020, 12, x FOR PEER REVIEW 15 of 25 
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Figure 7. Qualitative and quantitative analysis of MR volume images of sponge phantom. (a) Sponge
phantom diagram and fragment of the MRI image volume; (b) cropped sub-volumes; (c) histograms
of sub-volumes of the sponge phantom; (d) example of the resulted histograms obtained using
exchangeable sponge phantom wetted with a 0.03 mg/mL MOF suspension (11.25 µg of MOF per cm3 of
sponge volume)—Green arrows show the influence of MOF addition on the image intensity histogram;
i.e., decrease in maximum histogram value and expansion in the image intensity range towards
higher intensities (left); histogram maximum value versus MOF concentration in the sponge—The
red arrow points at the smallest therapeutic INH dose for inhalation per lung volume of 37.5 µg/cm3,
assuming rat weight of 300 g, lung volume of 3 cm3 and the fact that MOF constitutes 30% of optimized
INH-MOF-loaded PLGA/LC MP blend (right).
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Figure 8. Qualitative and quantitative analysis of MRI volume images of lungs. (a) Single slice from
the MRI image volume (left) and 3D projection of segmented lung image volume (right); (b) histograms
of volume lung images obtained for three different MOF concentrations (the grey arrows show the
influence of MOF concentration on the image intensity histogram; i.e., decrease in maximum histogram
value and expansion in the image intensity range towards higher intensities); (c) views of rendered left
lobe fine structure (the yellow circle shows details of deeper lung areas contrasted with MOF).
3.5. Time-Dependent Cellular Uptake
Our previous research proved that MOF MPs could be phagocytosed by fibroblasts [29]. On this
basis, in this work optimized INH-MOF-loaded PLGA/LC MP blend’s uptake in macrophages
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was investigated to assess the potential to target the primary site of TB infection and residency.
Time-dependent cellular uptake was investigated in RAW cells treated by the optimized, INH-MOF-
loaded PLGA/LC MP blend and INH-MOF for 0.5, 3, 6, and 24 h. The amount of INH encapsulated
in both samples was about 20 µg per well. Both INH-MOF and the optimized INH-MOF-loaded
PLGA/LC MP blend were internalized by macrophages and subsequently released inside the cells.
An increase in INH concentration was observed at each measurement time point, reaching after 24
h the maximum value of 16.66 ± 0.01 pg/cell for blend and 13.20 ± 0.01 pg/cell for INH-MOF. The
percentage of accumulated INH (after 24 h) in reference to total applied dose was 21.13% ± 0.02%
for the optimized INH-MOF-loaded PLGA/LC MP blend and it was 16.16% ± 0.36% for INH-MOF
(Figure 9).
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metabolic activity after 24 h of incubation was observed when compared to the control (116% ± 
2.5% and 113% ± 1.6%, respectively). After prolongation of the incubation time, no further increase 
is observed. At the highest concentration (500 μg/mL), the presence of MOF led to decrease of the 
cell viability by 52% (±2.2%) or 51% (±1.5%), respectively, after 24 or 72 h, in comparison with the 
control group. However, after 72 h the number of cells was still higher than that observed after 24 h; 
therefore, in MOF’s presence the proliferation and activity of macrophages were slowed down but 
Figure 9. Comparison of the INH amount [pg] accumulated in macrophages treated by optimized
INH-MOF-loaded PLGA/LC MP blend and INH-MOF. The amount of INH per cell was calculated
based on the relative number of cells designated using the ToxiLight test. The mean values and error
bars are defined as the mean and SD, respectively. ** p < 0.01, as determined by unpaired two-tailed
Student’s t-tests.
3.6. Cytotoxicity Study
In the presence of MOF in low to moderate concentrations (10–50 µg/mL), no effect on cell viability
was observed (Figure 10a). For the lowest concentrations (10 and 25 µg/mL) an increas in metabolic
activity after 24 h of incubation w s observed wh n c mpared t the control (116% ± 2.5% a d 113% ±
1.6%, respecti el ). After prol ngation of the incubation time, no further increase is obse ved. At the
highest concentration (500 µg/mL), the presence of MOF led to decrease of th cell viability by 52%
(±2.2%) or 51% (±1.5%), respectively, after 24 or 72 h, in com arison with the control group. However,
after 72 h the number of cells was still higher than that observed after 24 h; t erefore, in MOF’s presence
the proliferation and activity of macrophag s were lowed down but not inhibited. On this basis,
it may be determined that th highest concentration of MOF which can be considered as “safe” for the
cells is 100 µg/mL. The difference between the viability of cells incubated with MOF and the control
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group was only 5.1% (±2.3%) after 24 h and 8.9% (±1.2%) after 72 h. The cytotoxicity of pure MOF was
increased by 12.9% after 24 h and by 22.8% after 72 h, as compared to the untreated cells.
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Subsequently, the influence of INH-MOF and the optimized INH-MOF-loaded PLGA/LC MP
blend on the viability of the macrophages (Figure 11a) was determined. The powder concentrations
were calculated on MOF content determined as safe for the cells (ca. 100 µg/mL). After 24 h, an upward
trend in cell viability, measured as the mitochondrial activity of macrophages, was observed for both
Pharmaceutics 2019, 11, 687 18 of 25
INH-MOF and the optimized INH-MOF-loaded PLGA/LC MP blend. This decrease was not substantial
enough to confirm the cytotoxic effect of MOF on macrophages. Additionally, there was observed
doubled level of produced reactive oxygen species (ROS) for cells incubated with INH-MOF and the
optimized INH-MOF-loaded PLGA/LC MP blend compared to untreated cells. However, it was still
much lower (13 times) than ROS concentration obtained for the positive control group (treated with
100 µM H2O2 solution) (Figure 11a). The morphology of macrophages changed—After 24 h, cells
become more rounded and some of them were swollen and a phagocytized MPs were observed inside
(Figure 11b).
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positive control (+C) (100 µM solution of H2O2 treated) and untreated cells (C). The mean values and
error bars are defined as the mean and SD, respectively. *** p < 0.001 as determined by unpaired,
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4. Discussion
As reported previously, merely aerosolizing anti-TB drugs may not be sufficient to provide
effective therapy [44]. For reaching deep lung levels and efficient antibacterial action, drugs need to be
formulated into delivery systems ensuring their uptake into alveolar macrophages where bacilli are
located. The obtained optimized INH-MOF-loaded PLGA/LC MP blend showed good aerodynamic
properties (%FPF = 56.7) and the ability to penetrate into the interior of macrophages (INH uptake
after 24 h was 21% of the dose).
The MOF’s safety as confirmed in our previous and current in vitro studies, which showed
that MOF did not cause a cytotoxic effect and did not inhibit L929 fibroblast proliferation even at a
high concentration (1.25 mg/mL) [29]. Moreover, iron carboxylate MOF’s safety has been proven in
in vivo studies conducted by Horcajada et al. [28], with complete MOF elimination and no side effects
(after 3 months from i.v. injection, 220 mg/kg). Additionally, we proved that MOF, INH-MOF, and the
optimized INH-MOF-loaded PLGA/LC MP blend did not cause a cytotoxic effect on macrophages.
In the previous study, MOF incubated for 24 h with L929 fibroblasts was phagocytosed and clearly
visible inside the cells in microscopic pictures, which suggests that MOF could release the drug inside
the cells; however, there is no evidence of INH uptake by macrophages [29]. In this study, we quantified
the amount of INH inside the macrophages and examined the formulation effect on the cellular uptake.
Results (Figure 8) indicate that both INH-MOF and the optimized INH-MOF-loaded PLGA/LC MP
blend were internalized by the macrophages and higher uptake was observed for the blend (16.66 ±
0.01 pg/cell for blend and 13.20 ± 0.01 pg/cell for INH-MOF after 24 h). An increase of INH concentrate
on inside the macrophages was observed during the whole experiment, which is not surprising, since
PLGA activates alveolar macrophage phagocytosis and is often used to increase the local concentration
of drugs within cells [45–47].
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The observed increase in the ROS level after 24 h of incubation with the blend, in concentrations
as high as 500 µg/mL, may support the antibacterial activity of INH against Mycobacteria. Additional
effects of the Fe3+ ions against the bacterial growth and survival have been already reported [48–52].
The observed release of INH is a result of the concerted action of PLGA and INH-MOF and LC
and INH-MOF. There are a few levels in drug dissolution: (1) INH release from INH-MOF located
on the PLGA MPs surface (Figure 3b); (2) INH-MOF release from microparticles (LC or PLGA); and
(3) INH release from MOF. Release of INH from LC MPs roughly resembled release of INH from
pure INH-MOF NP’s (see Figures 4 and 6 in Wyszogrodzka et al.) [31]. Naturally, the choice of
PLGA as a long-term releasing polymer caused further retardation in INH release from INH-MOF
NPs and increased drug residence time in the lungs. The choice was governed by the rather limited
arsenal of accepted materials for lung drug delivery. To date, this is perhaps the major limitation to
commercialization of new and more effective inhaled formulations, able to grant sufficient local and
systemic antibiotic levels [34].
The selection of excipients for inhaled formulations requires serious consideration of the therapy
requirements. In fact, the use of excipients in pulmonary drug delivery, albeit necessary to provide the
required aerodynamic and rheological properties, can be a considerable pitfall for inhaled antibiotic
therapies, since it can determine the need for an excessive aerosolized mass of material to reach the
required effective dose. Whether the goal is targeting pathogen’s niches or grant local and systemic
therapeutic levels, a high drug concentration and low amount of excipient are desirable, because
the quantity of material that the patient is able to inhale without adverse events sets the size of
the therapeutic window [53]. Naturally, if the aim of the therapy is to target macrophages, the
excipients should provide a slower dissolution rate, for prolonged internalization by phagocytosis [33].
Unfortunately, although there are many examples of inhaled INH formulations in the literature, there
is still no inhaled anti-TB product available on the market, and therefore dose-determining criteria
are lacking [44,54]. In light of such considerations, our approach was based on the blending of two
kinds of particles, each one embedding the drug-MOF complex, in order to fulfill the above-mentioned
requirements for pulmonary drug delivery and limit the drug dilution effect which undermines the use
of microencapsulated drugs in inhaled therapies. In our case, the drug delivery and MRI tracking agent
double role of the optimized MP blend may contribute to ensuring the required delivered dose and
helping to determine the clinical relevance of the proposed approach owing to the possibility of MRI
tracking. This fundamental property was evaluated by using sponges as a heterogenous lung phantom.
Such lung simulating systems, albeit clearly rather simplified, have been applied in several
studies because of the pore size distribution—Ranging from sub-millimeter to a few millimeters with
sub-millimeter pores located in the walls of large pores [55]. They have been used as phantoms
for lung ultrasound surface wave elastography [55] and for lung MR imaging [56]. Different MRI
pulse sequences, including FSE (fast spin echo) and PROPELLER (periodically rotated overlapping
parallel lines with enhanced reconstruction), have been tested, during the last decade, for detection
and identification of different pulmonary changes induced by tuberculosis [9–11]. These methods are
not particularly effective for imaging of lung tissue, characterized by fast signal decay due to very
short T2/T2* relaxation times. In turn, the UTE MRI pulse sequence overcomes this issue since the
signal can be acquired starting at tens of microseconds. Therefore, UTE has been successfully applied
for ex vivo [15,16] and in vivo [17,18] studies on lung aerosol deposition, and on a study on sponge
phantoms simulating lung structure [56].
The main goal of in vitro imaging experiment was to assess MRI contrast possibilities for extremely
low MOF concentrations (i.e., to estimate sensitivity) in a highly inhomogeneous environment
mimicking lung tissue. The smallest therapeutic INH dose for inhalation was set according to
Zhou et al. (2005) as 1% of an oral dose [57]. With this assumption MOF concentration per lung volume
was 37.5 µg/cm3 (assuming rat weight of 300 g, lung volume of 3 cm3, and the fact that MOF constitutes
30% of optimized INH-MOF-loaded PLGA/LC MP blend). This minimal dose was marked in the right
panel of Figure 7d. It should be noted, that even for doses below 1% of the oral INH dose the MRI
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contrast was achieved in terms of image histogram parameters—In this case maximum histogram
value. Lowering the maximum histogram value moved more voxel counts towards higher image
intensities; i.e., gave positive contrast. However, for the MOF concentration in this range there was no
unambiguous dependence of the maximum histogram value on MOF concentration and its values
were in the range 0.7–0.9 of that obtained for pure water. But, 10% of an oral dose corresponded
to a MOF concentration of 375 µg/cm3, which was equal to the highest tested MOF concentration.
In this case the maximum histogram value was 0.6 of that obtained for pure water. The 50% of the oral
dose was located outside the concentrations range covering the MOF concentration axis in the right
panel of Figure 7d. Thus, it means that the most probable inhalable therapeutic INH concentration,
which corresponds to 50% of the INH oral dose, would assure excellent contrast [58,59]. A UTE3D
imaging pulse sequence with very short TE of 110 micros and short TR of 2345 ms will generate T1
weighted images. The effect will be visible even for small or moderate change in T1, while even large
change in T2/T2* will not affect MR image much due to the ultra short TE. In our study, the 3D UTE
MRI allowed for effective T1 weighing for an environment characterized by large spatial magnetic
susceptibility gradients; i.e., large air voids and thin water layers inside the sponge—the structure
resembling lung tissue.
Contrast possibilities of the optimized INH-MOF-loaded PLGA/LC MP blend (final INH-MOF-
loaded PLGA/LC formulation) were consequently confirmed on extracted rat respiratory tract. On one
hand, histograms of the MR images of rat lungs followed similar pattern/dependence of MOF
concentration as obtained on sponge fantom. On the other hand particles of an optimized blend were
able to reach tertiary bronchi structure, and consequently providedthe possibility to visualize them
(see the lower panel of Figure 8c). Accounting for, very likely, a not efficient administration method,
post mortem administration and the much smaller rat lung structure (as compared with human)
indirectly corresponds to impinger results obtained for the optimized INH-MOF-loaded PLGA/LC
MP blend. Concerning the size difference, the linear diameter of left (main) bronchia is 9.5 times
larger in humans than in rats [60]. For this reason, it should be noted that adopting the inhalatory
dry powder formulation to the small animal species should not be recommended. The reason is that
aerodynamic properties do not change according to the species, but what is changing is the anatomy,
size, and physiological features of the lungs that cannot be completely accounted for when engineering
respirable particles. Moreover, the target is always humans; therefore, changing the formulation to
adjust it according to animal species would be pointless.
Both MRI experiments, i.e., on sponge phantom and consequent ex vivo experiment, constituted
the final step of the complete proof of concept study. The INH concentration in the MRI study, was based
on published small animals studies, although the effectiveness of inhalable approach to INH-containing
MPs administration has been proven in studies on large animals in vivo. Verma et al. [61] have
administered inhaled MPs containing INH to rhesus macaques in the following single dosages: 0.25,
2.5, and 25 mg. They observed that the intracellular INH concentration in alveolar macrophages was
below limits for the lowest dose. Since the level of the drug in tissue homogenate is proportional
to the level of the drug in macrophages, then, even for the lowest dose tested, the drug will be
present in macrophages. Thus, it has been concluded that dose levels between 0.25 and 2.5 mg
would be appropriate for humans, which corresponds to the 4% w/w INH content in the optimized
INH-MOF-loaded PLGA/LC MP blend. Verma et al. indicated also that the inhaled dose must be kept
at a low level to target alveolar macrophages and especially that dry powder inhalation may cause
significant systemic bioavailability. It is noteworthy that there is no guideline to determine the correct
dose of INH for inhalation for humans and all attempts to date to determine it relate to a fixed oral
dose. Although, taking into account the complexity of inhaled administration and the dependence on
patient physiology and pathological changes, determining one correct dose is the wrong approach,
as opposed to personalization, which is possible thanks to theranostics. In spite of all, recent studies
conducted on monkeys [52] indicate the high potential of inhalation therapy in both local and systemic
therapy, or inhalation therapy supporting an oral therapy, each time allowing for dose reduction and
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increased treatment efficacy. Therefore, our approach may be suitable to meet clinical needs in inhaled
TB therapy.
At the end of the discussion it should be noted that further modifications of the obtained, MOF
based dosage form to inhalation are possible. Considering that TB treatment requires multi-drug
therapy, we want to point out that the solution containing only INH was thought of as a starting
platform in order to understand feasibility of INH-MOF theranostic inhalatory formulation. Moreover,
the proposed multiparticle approach based on blending has the advantage of allowing the addition of
different drugs embedded in different particle formulations by simple mixing of the different delivery
systems. By this principle it would be easy to add multiple drugs encapsulated in different particles in
order to obtain a multidrug delivery system in which the single drug can be reciprocally combined
according to precise ratios.
5. Conclusions
The study presents a complete proof of concept of the development of an MOF-based, inhalable
theranostic system for tuberculosis treatment. Using INH-MOF nanoparticles as a starting material
assuring modified INH release, spray-drying technology allowed us to obtain a theranostic, optimized,
INH-MOF-loaded PLGA/LC MP blend with:
• Good aerodynamic properties combined with controlled release of INH;
• Improved absorption of the formulation by macrophages;
• Promising contrast properties enabling monitoring of the distribution of formulation within the
inhomogeneous structure of the lungs.
To date, this study represents the first attempt to fabricate MOF-based, inhaled formulation to be
administered by a dry powder inhaler, combining drug delivery and magnetic resonance imaging
contrast agent functionality.
The successful development of such MOF inhalable theranostic platforms will enable personalized
delivery of active substances to the lungs and greatly contribute to the increase of inhaled therapeutic
efficacy. In fact, as pulmonary antibiotic treatment requires careful control of the delivered dose, MRI
monitoring upon administration may grant important benefits for the development of inhaled TB
personalized medicines.
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Abbreviations
%ED emitted dose;
%FPF fine particle fraction;
3D UTE three-dimensional ultra short echo time;
ACN acetonitrile;
INH isoniazid;
INH-MOF complex of isoniazid and MOF;
LC leucine;
MOF metal-organic framework;
MP microparticles;
MRI magnetic resonance imaging;
PLGA poly (lactic-co-glycolic acid);
ROS reactive oxygen species;
TB tuberculosis;
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